Advertisement

Volume 130, Issue 12

Cover Figure: PIM kinases as novel common targets in Hodgkin lymphoma. See the article by Szydłowski et al.

WASHINGTON, September 21, 2017 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Signal integration at the PI3K-p85-XBP1 hub endows coagulation protease activated protein C with insulin-like function
Madhusudhan et al elegantly demonstrate a novel role of activated protein C in maintaining endoplasmic reticulum homeostasis and cellular metabolism in diabetic kidney disease.

Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma
The role of PIM kinases in Hodgkin lymphoma is currently unknown. The impact of this study lies in its identification of PIM kinases as ubiquitously expressed immunoregulatory molecules that promote tumor cell survival in classical Hodgkin lymphoma.

A MALT lymphoma prognostic index
This is the only retrospective analysis of a prospective clinical trial in mucosa-associated lymphoid tissue (MALT) lymphomas evaluating prognostic factors and generating a robust prognostic index validated in an independent cohort, providing further support to the MALT International Prognostic Index.

Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E)
Over the last 3 years, a veritable explosion of genomic data has shed light on the mutational landscape of cutaneous T-cell lymphoma (CTCL). Park et al add important new knowledge and improve the resolution of the known mutational map of CTCL.

Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial
This study provides a long-term update on the outcomes of patients with chronic lymphocytic leukemia (CLL) who underwent a matched related or unrelated allogeneic stem cell transplant with a reduced-intensity fludarabine/alkylator-based approach for high-risk disease.

New oncogenic subtypes in pediatric B-cell precursor acute lymphoblastic leukemia
This Blood Spotlight review highlights novel genetic subtypes and defines genetic changes that may provide new targets for therapy.

How I treat pediatric venous thromboembolism
This article gives an overview of the challenges faced in treating a pediatric patient with thrombosis and outlines 3 case scenarios which highlight many of the issues that commonly arise.

Hematopoietic stem cell transplantation in 29 patients hemizygous for hypomorphic IKBKG/NEMO mutations
Miot et al report encouraging results of a retrospective analysis of the clinical outcome of stem cell transplantation in patients with hypomorphic mutations in the gene IKBKG, which encodes NF-κB essential modulator (NEMO), and provide insight in how to perform transplants on these patients.

 

This week's complete table of contents

Why Submit to Blood?

 


 

Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.